Skip to main content

Table 3 One-year follow-up univariate and multivariate survival analysis in FIGO stage III-IV for FOLR1 mRNA expression

From: Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers

   

Univariatea

Multivariateb

   

PFS

OS

PFS

OS

   

Months (median)

CI 95 %

HR

p value

Months (median)

CI 95 %

HR

p value

HR

CI 95 %

p value

HR

CI 95 %

p value

Type I

FOLR1 mRNA expressionc

Weak

8.56

7.06-10.06

0.246 [0.081-0.743]

0.006**

10.25

9.06-11.44

0.093 [0.012-0.717]

0.004**

0.38

0.16-0.87

0.023*

0.59

0.007-0.52

0.011*

 

Strong

11.25

10.08-12.41

11.64

10.95-12.33

 

Grading

G1 VS G2-3

        

0.62

0.35-1.65

0.416

1.11

0.29-4.18

0.880

 

Age

< o > median

        

0.76

0.36-1.58

0.461

1.46

0.69-3.05

0.317

 

Residual disease

0 VS >0

        

2.04

0.71-5.83

0.183

1.33

0.37-4.29

0.661

 

histologyd

         

1.73

0.94-3.37

0.077

2.01

0.94-4.29

0.071

 

FIGO stage

I-II VS III-IV

        

2.08

0.84-5.11

0.110

1.01

0.30-3.83

0.982

Type II

FOLR1 mRNA expressionc

Weak

9.17

7.94-10.40

0.904 [0.577-1.414]

0.183

11.25

10.38-12.12

0.586 [0.170-2.023]

0.390

      
 

Strong

10.30

9.57-11.02

11.68

11.30-12.05

      
  1. Cut off for FOLR1 mRNA expression = median value in the cancer cohort (9.14) *Significant at the 0.05 level, **Significant at the 0.01 level alog rank test, bCOX-regression analysis;
  2. cArbitrary units normalized to TBP. dSerous, endometrioid, mucinous and clear cell. Multivariate analysis was performed if p-value in univariate analysis was > 0.1
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us